New drug combo offers hope for patients with advanced cancers
NCT ID NCT06911827
First seen Feb 28, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests two experimental drugs, QLP2117 and QL2107, together in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 149 participants will receive the drugs in increasing doses to find the best dose and measure any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.